Yale-Griffin Prevention Research Center to Study Effects of Chromium Picolinate in People with Pre-Diabetes
August 2, 2004
NIH-funded Clinical Trial to Evaluate Potential Benefit of
Nutritional Supplements on Blood Glucose & Heart Health
DERBY, Conn., July 22 /PRNewswire/ -- The Yale-Griffin Prevention Research
Center (PRC), a collaboration between Griffin Hospital and the Yale School of
Epidemiology and Public Health, announced the start of a double-blind,
randomized, placebo-controlled clinical trial to study the effects of chromium
supplementation on blood glucose levels and endothelial function in people
with pre-diabetes. The two-year pilot study is funded by a grant from the
National Institutes of Health's (NIH) National Center for Complementary and
Alternative Medicine (NCCAM).
"The aim of this clinical trial is to further explore the benefit of
nutritional intervention with chromium picolinate, before pre-diabetes
progresses into a chronic disease state," explains Dr. David Katz, director of
the Yale-Griffin Prevention Research Center and principal investigator of the
new study. "In pre-diabetes, pharmacotherapy may not yet be justified or
acceptable for patients. Chromium has shown potential to serve as a safe and
affordable adjunct nutritional therapy, as part of a preventive approach."
Pre-diabetes, also known as Impaired Glucose Tolerance (IGT), affects
approximately 41 million Americans and is a pre-cursor to type 2 diabetes and
cardiovascular disease. The American Diabetes Association (ADA) defines pre-
diabetes as a condition where blood sugar levels are higher than normal, but
not high enough to be diagnosed as type 2 diabetes.
Sixty (60) patients will include adult men and women, who have been
identified as "pre-diabetic". The study will compare the effects of 500 mcg
and 1,000 mcg of chromium picolinate daily on glucose tolerance, compared with
a placebo control group. Glucose tolerance will be measured by fasting
insulin and 2-hour post 75 g oral glucose tolerance test (OGTT).
People with pre-diabetes have a 1.5-fold risk of cardiovascular disease
compared to people with normal blood glucose. Importantly, the study will
also measure the effects of chromium supplementation on endothelial function,
a marker of vascular health and heart disease risk. Endothelial function will
be measured by an ultrasound test of the brachial artery in the arm, a non-
A number of studies have shown that chromium in the form of chromium
picolinate helps reduce insulin resistance, improve blood sugar control, and
may help reduce risk of cardiovascular disease and type 2 diabetes. "Chromium
picolinate was selected for this study, because it is the most commonly used
and chemically stable form of the mineral," according to Dr. Katz. Nutrition
21 will supply Chromax(R) chromium picolinate for the clinical trial.
Yale-Griffin Prevention Research Center
The Yale-Griffin Prevention Research Center (PRC) was established in 1998
through a 5-year, nearly $3 million grant from the Centers for Disease Control
(CDC). One of 28 such centers nationwide, each of which represents an
academic/community partnership, the Yale-Griffin PRC is the only center in the
network based in a hospital. The PRC is committed to research pertaining to
the primary, secondary, & tertiary prevention of chronic disease that is
responsive to the priorities of local residents in the Lower Naugatuck Valley
of CT, the residents of Connecticut's major cities, and other communities
throughout the state. The center is dedicated to participatory research
methods, to a robust research agenda inclusive of developmental/determinant,
intervention, and translational research; to community involvement in public
health; to the eradication of disparities in health and health care in the
communities served; and to the dissemination of effective interventions in
support of the national objectives of Healthy People 2010.
SOURCE Yale-Griffin Prevention Research Center
Be the first to comment on this article!